SCHEMBL1557557

SCHEMBL1557557

CC1(C)OB(c2ccc(C(N)=O)cc2N)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
CA1 P00915 5/20 0.36
CA2 P00918 5/20 0.36
CA9 Q16790 5/20 0.36
TSHR P16473 1/20 0.36
F11 P03951 2/20 0.35
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
PARP1 P09874 2/20 0.35
MAPT P10636 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
LCK P06239 1/20 0.34
BRD4 O60885 1/20 0.34
BRPF1 P55201 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CXCR2 P25025 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753270 0.84 PARP1 (0.39) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL2823437 0.84 PARP1 (0.39) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL30803515 0.84 KDM4E (0.53) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL1558587 0.84 PLAU (0.40) CA1CA2CA9TSHRSMN1; SMN2
SCHEMBL17181493 0.84 KDM4E (0.53) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL15556525 0.83 PARP1 (0.38) CA1CA2CA9TSHRF11
SCHEMBL1674267 0.83 PARP1 (0.38) CA1CA2CA9TSHRF11
Hydrochloric Acid SCHEMBL19475161 0.82 KDM4E (0.51) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL1347543 0.81 MAPK14 (0.39) ALDH1A1KDM4EHSD17B10CA1CA2
SCHEMBL18181649 0.81 MAPK1 (0.48) ALDH1A1CA1CA2CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178070-A1 PI3K/mTOR INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-07-21 US disclosed
EP-2311842-A2 PI3K/M TOR inhibitors Takeda Pharmaceutical Company Limited (JP) 2011-04-20 EP disclosed
EP-2303886-A2 PI3K/M TOR INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-04-06 EP disclosed
WO-2010008847-A2 PI3K/M TOR INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178070-A1 PI3K/mTOR INHIBITORS MTOR, RICTOR, PIK3CA ALDH1A1 4277/4885KDM4E 643/4885HSD17B10 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.